Genmab shares surged after encouraging clinical-trial results for an experimental colorectal cancer treatment, highlighting how drug-development milestones can reshape biotechnology valuations. European equities also recovered as investors weighed corporate earnings, easing oil prices and upcoming central-bank decisions.
│ ◉ Shares surge: Genmab gained 13.7% in Monday trading following encouraging follow-up data from its experimental cancer treatment.
│ ◉ Clinical progress: Phase 2 results showed promising tumour-response rates, although larger trials are needed to establish the treatment’s benefits.
│ ◉ Market recovery: The STOXX Europe 600 rose 0.4% to 638.45 points as improving German business sentiment supported equities.
European markets began the week on firmer footing, with biotechnology shares attracting attention as investors assessed new clinical evidence alongside broader economic developments.
Danish biotechnology company Genmab became one of the session’s strongest performers, with its shares climbing 13.7% on 26 October. The move followed updated Phase 2 results for petosemtamab, an experimental antibody being evaluated in combination with chemotherapy for patients with metastatic colorectal cancer.
The latest analysis reported objective response rates of 75% among evaluable first-line patients and 67% among second-line patients, combining confirmed and unconfirmed responses. The median follow-up periods were 5.9 months and 7.1 months, respectively.
These findings provide a potential foundation for further development, but the distinction between preliminary efficacy and established clinical benefit remains important. Phase 2 studies typically involve relatively small patient groups, and response rates alone do not determine whether a treatment will ultimately receive regulatory approval or achieve commercial success.
Why Clinical Milestones Matter
Biotechnology companies are often valued differently from established pharmaceutical businesses. Their financial outlook can depend heavily on experimental treatments that have yet to generate revenue.
A positive clinical update can change expectations about a drug’s probability of success, its potential market and the company’s future revenue opportunities. When investors revise these assumptions simultaneously, share-price movements can be substantial.
However, development costs, safety considerations, regulatory requirements, competition and the time needed to reach commercialisation remain significant uncertainties.
Genmab’s latest results are particularly relevant because petosemtamab is advancing through a broader clinical development programme that includes Phase 3 trials. These larger studies are intended to provide more robust evidence of efficacy and safety.
European Markets Recover
The broader market environment also contributed to the session’s improvement. The STOXX Europe 600 advanced 0.4% to 638.45 points by 1050 GMT on Monday, while Germany’s DAX gained 0.9% following stronger-than-expected business sentiment data.
Lower oil prices offered some relief after energy costs and political uncertainty had weighed on European equities during the previous week.
Attention remained on corporate earnings and upcoming monetary-policy decisions from the European Central Bank and the US Federal Reserve. These developments could influence borrowing costs, currency markets and company valuations across sectors.
The Bigger Picture
Genmab’s rally demonstrates how company-specific clinical developments can outperform the broader market narrative, even when investors remain focused on inflation, energy prices and monetary policy.
The central question is whether promising early results can translate into reproducible clinical benefits, regulatory approval and sustainable commercial revenue.
For biotechnology valuations, that transition from scientific promise to demonstrated outcomes remains a defining source of both opportunity and uncertainty.
